clinical trial · NCT04793958
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Mirati Therapeutics Inc.·phase3·active not recruiting·n = 461
Advanced Colorectal CancerMetastatic Colorectal CancerMRTX849CetuximabmFOLFOX6 RegimenFOLFIRI Regimen
brief summary
Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.
started
Jun 24, 2021
primary completion
Jan 16, 2026
completion
Jul 31, 2026
last updated
Jul 23, 2026
official title
A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol